<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VALACYCLOVIR HYDROCHLORIDE</span><br/>(val-a-cy'clo-vir)<br/><span class="topboxtradename">Valtrex<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Acyclovir<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>An antiviral agent hydrolyzed in the intestinal wall or liver to acyclovir; interferes with viral DNA synthesis. Because of
         increased GI absorption, the plasma level of this drug is substantially higher than that of acyclovir when both are taken
         orally.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), varicella zoster virus, and cytomegalovirus. Inhibits viral
         replication.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Herpes zoster (shingles) in immunocompetent adults. Treatment and suppression of recurrent genital herpes; suppression of
         recurrent herpes in HIV-positive patients; treatment of cold sores.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to or intolerance of valacyclovir or acyclovir; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, patients receiving nephrotoxic drugs, advanced HIV disease, allogeneic bone marrow transplant and renal
         transplant recipients, treatment of disseminated herpes zoster, immunocompromised patients, lactation. Safety and efficacy
         in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Herpes Zoster</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 g (2 <small>x</small> 500 mg) t.i.d. for 7 d, start within 48 h of onset of zoster rash<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3049 mL/min: 1 g q12h 1029 mL/min: 1 g q24h <br/><span class="indicationtitle">Treatment of Recurrent Genital Herpes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg b.i.d. <small>x</small> 3 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <img src="../images/special/lesserorequal.gif"/>29 mL/min: 500 mg q.d.<br/><br/><span class="indicationtitle">Suppression of Recurrent Genital Herpes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 g q.d.<br/><br/><span class="indicationtitle">Treatment of Cold Sores</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g 12 h <small>x</small> 2 doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Start drug as soon as possible after diagnosis of herpes zoster, preferably within 48 h of onset of rash.</li>
<li>
            				Note: Dosage reduction is recommended for patients with renal impairment.
            			
         </li>
<li>Give valacyclovir after hemodialysis.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> weakness, somnolence, dizziness, fatigue, lethargy, confusion. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span> abdominal pain, dyspepsia, flatulence. <span class="typehead">Urogenital:</span> Glomerulonephritis, renal tubular damage, acute renal failure. <span class="typehead">Skin:</span> Rash, urticaria, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid,</b>
<b>cimetidine</b> decrease valacyclovir elimination. <b>Zidovudine</b> may cause increased drowsiness and lethargy. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 54% reaches systemic circulation as acyclovir. <span class="typehead">Peak:</span> 1.5 h. <span class="typehead">Distribution:</span> 13.517.9% bound to plasma proteins; distributes into plasma, cerebrospinal fluid, saliva, and major body organs;
      crosses placenta; excreted in breast milk. <span class="typehead">Metabolism:</span> Rapidly converted to acyclovir during first pass through intestine and liver. <span class="typehead">Elimination:</span> 4050% excreted in urine. <span class="typehead">Half-Life:</span> 2.53.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor kidney function in patients with kidney impairment or those receiving potentially nephrotoxic drugs.</li>
<li>Monitor for S&amp;S of hypersensitivity; if present, withhold drug and notify physician.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of potential adverse effects and do not discontinue drug until full course is completed.</li>
<li>
            							Note: Post-herpes pain is likely to be present for several months after completion of therapy.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>